Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in pediatric heart failure with left ventricular systolic dysfunction
2024-519829-38-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and left ventricular systolic dysfunction (LVSD) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in NT-proBNP from baseline to 3 months. Planned start Jan 2026; status: authorised.
02
Drugs
finerenone
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2024-519829-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519829-38-00.